Global Nanomedicine Market 2017-2023: Emergence of Nanorobotics to Drive the Growth of the $392 Billion Industry - Research and Markets

DUBLIN, Mar 17, 2017 /PRNewswire/ --

Research and Markets has announced the addition of the "Global Nanomedicine Market - Drivers, Opportunities, Trends, and Forecasts: 2017-2023" report to their offering.

The Nanomedicine Market to Grow at a CAGR of 17.1% During the Forecast Period 2017-2023 to Aggregate $392.80 Billion By 2023

The nanomedicine market is analyzed based on two segments - therapeutic applications and regions.

The major drivers of the nanomedicine market include its application in various therapeutic areas, increasing R&D studies about nanorobots in this segment, and significant investments in clinical trials by the government as well as private sector. The Oncology segment is the major therapeutic area for nanomedicine application, which comprised more than 35% of the total market share in 2016. A major focus in this segment is expected to drive the growth of the nanomedicine market in the future.

Moreover, nanomedicines are introducing new therapeutic opportunities for a large number of agents that cannot be used effectively as conventional oral formulations due to poor bioavailability. The therapeutic areas for nanomedicine application are Oncology, Cardiovascular, Neurology, Anti-inflammatory, Anti-infectives, and various other areas.

Globally, the industry players are focusing significantly on R&D to gain approval for various clinical trials for future nano-drugs to be commercially available in the market. The FDA should be relatively prepared for some of the earliest and most basic applications of nanomedicine in areas such as gene therapy and tissue engineering. The more advanced applications of nanomedicine will pose unique challenges in terms of classification and maintenance of scientific expertise.

Key Topics Covered:

1 Industry Outlook
1.1 Industry Overview
1.2 Industry Trends
1.3 PEST Analysis

2 Report Outline
2.1 Report Scope
2.2 Report Summary
2.3 Research Methodology
2.4 Report Assumptions

3 Market Snapshot
3.1 Total Addressable Market (TAM)
3.2 Segmented Addressable Market (SAM)
3.3 Related Markets
3.3.1 mHealth Market
3.3.2 Healthcare Analytics Market

4 Market Outlook
4.1 Overview
4.2 Regulatory Bodies and Standards
4.3 Government Spending and Initiatives
4.4 Porter 5 (Five) Forces

5 Market Characteristics
5.1 Evolution
5.2 Ecosystem
5.2.1 Regulatory Process
5.2.2 Clinical Trials
5.2.3 Pricing and Reimbursement
5.3 Market Segmentation
5.4 Market Dynamics
5.4.1 Drivers
5.4.1.1 Emergence of nanorobotics
5.4.1.2 Applications and advantages of nanomedicine in various healthcare segments
5.4.1.3 Reasonable investments in R&D
5.4.1.4 Increased support from governments
5.4.2 Restraints
5.4.2.1 Long approval process and stringent regulations
5.4.2.2 Problems regarding nanoscale manufacturing
5.4.2.3 Risks related to nanomedicines
5.4.2.4 Undefined regulatory standards
5.4.3 Opportunities
5.4.3.1 Aging population with chronic care needs
5.4.3.2 Population and income growth in emerging countries
5.4.4 DRO - Impact Analysis

6 Trends, Roadmap and Projects
6.1 Market Trends and Impact
6.2 Technology Roadmap

7 Types: Market Size and Analysis
7.1 Overview
7.2 Global Nanomedicine Market in Oncology Segment
7.3 Global Nanomedicine Market in Cardiovascular Segment
7.4 Global Nanomedicine Market in Neurology Segment
7.5 Global Nanomedicine Market in Anti-inflammatory Segment
7.6 Global Nanomedicine Market in Anti-infective Segment
7.7 Global Nanomedicine Market in Other Therapeutic Areas

8 Trending Nanomedicines
8.1 Overview
8.2 Abraxane
8.3 Alimta
8.4 Eligard
8.5 Copaxone
8.6 Rapamune
8.7 Neulasta
8.8 Cimzia
8.9 AmBisome
8.10 Mircera
8.11 Pegasys
8.12 Emend
8.13 Renagel
8.14 Ritalin

9 Regions: Market Size and Analysis
9.1 Overview
9.1.1 Global Nanomedicine Market by Geographical Segmentation
9.2 Key Leading Countries
9.2.1 US
9.2.2 Germany
9.2.3 Japan

10 Vendor Scenario

11 Vendor Profiles
11.1 Merck & Co. Inc.
11.2 Hoffmann-La Roche Ltd.
11.3 Gilead Sciences
11.4 Novartis AG
11.5 Amgen Inc.

12 Global Generalist
12.1 Pfizer Inc.
12.2 Eli Lilly and Company
12.3 Sanofi

13 Companies to Watch for
13.1 Nanobiotix SA
13.2 UCB SA

14 Market Landscape

For more information about this report visit http://www.researchandmarkets.com/research/krjtrq/global

Media Contact:

Research and Markets
Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Related Links

http://www.researchandmarkets.com

SOURCE Research and Markets